Novartis and FDA hail 'historic' Kymriah, first ever approved CAR-T

Novartis HQ

In the end, the FDA took little more than six weeks to give final approval to Kymriah, the first ever CAR-T treatment.

The US regulators’ advisors recommended the drug last month, and now the agency has itself backed the drug for use in patients, an historic advance in treating patients with acute lymphoblastic leukemia (ALL), which is set to be the first of many haematological cancers to be targeted.

Kymriah (tisagenlecleucel, known as CTL019 until now) is the first chimeric antigen receptor T cell (CAR-T) therapy, and will now be available for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

The novel immunocellular therapy is an historic first because it is the first gene transfer treatment approved by the FDA, and uses a patient’s own T cells to fight cancer.

The Swiss pharma giant has beaten its closest rival, Kite Pharma, to the market,  though its CAR-T treatment is not far behind, looking set for approval in November.

Novartis has already declared that a one-time treatment of the drug will cost $475,000 -  within the range predicted by analysts, but much lower than the $1 million forecasts made initially.

This price reflects that for some patients, the treatment will be seen only as a bridge to transplantation, and therefore only a part of the overall treatment cost.

A big step forward in blood cancers

The promise of the CAR-Ts is enormous for patients with relapsed or refractory ALL, who otherwise face a death sentence after all other therapies have failed.

A pivotal clinical trial of Kymriah in 63 paediatric and young adult patients with the condition found overall remission – a complete absence of the disease -  in 83% of patients within three months of treatment.

If this response proves durable, at least for some patients, it could represent a cure.

Novartis has triumphed in being the first company to bring a CAR-T to market, thanks to its work with immunologist Carl June, one of the earliest pioneers of the technology at the University of Pennsylvania Perelman School of Medicine.

"At Novartis, we have a long history of being at the forefront of transformative cancer treatment," said Joseph Jimenez, CEO of Novartis. "Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need. With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care."

"This therapy is a significant step forward in individualised cancer treatment that may have a tremendous impact on patients' lives," said Carl June, MD, the Richard W. Vague Professor of Immunotherapy, Director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine.

[caption id="attachment_31211" align="alignnone" width="159"]CAR-T pioneer Carl June CAR-T pioneer Carl June[/caption]

"Through our collaboration with Novartis, we are creating the next wave of immunocellular cancer treatments, and are eager to progress CAR-T therapy in a host of haematologic and other cancer types."

The FDA Commissioner, Scott Gottlieb, also took the rare step of commenting on a new approval himself.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said Gottlieb.

“New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”

Safety measures

Like other CAR-T treatments in development, Kymriah does carry significant safety risks. The greatest of these is cytokine release syndrome (CRS), an immune system firestorm which has proven fatal in some CAR-T trials.

In the study, 49% of patients treated with Kymriah experienced grade 3 or 4 CRS, however there were no incidents of the cerebral oedema seen in trials of other CAR-T candidates from Kite Pharma and Juno.

The FDA has approved a Risk Evaluation and Mitigation Strategy (REMS), to inform patients and doctors about the risks and monitor safety.

The arrival of CAR-Ts and other gene and cell therapies will also mean that specialist treatment centres will have to be established to administer the drugs. Novartis is also establishing a network of certified treatment centres throughout the country which will be fully trained on the use of Kymriah and appropriate patient care.

Gilead in the picture

The timing of the approval is remarkable, coming just two days after Gilead announced it is buying Novartis’ close CAR-T rival, Kite Pharma for $12 billion.

Analysts will watch closely for how Gilead/Kite will price its rival Axi-cel once it gains approval. Currently under priority review by the FDA, its decision date is 29 November, but a ruling could come earlier as it has with Novartis.

Novartis says it intends to launch a variety of US patient access programmes to support access for patients, including the standard measures to help patients navigate insurance coverage and providing financial assistance for the uninsured or underinsured.

The company plans additional filings for Kymriah in the US and EU later this year, including applications with the FDA and EMA, for the treatment of adult patients with r/r diffuse large B-cell lymphoma (DLBCL). Additional filings beyond the US and EU are anticipated in 2018.

Outcomes-based approach

Novartis has also announced a novel collaboration with the United States Centers for Medicare and Medicaid Services (CMS) centred around  indication-based pricing and outcomes-based payment.

The indication-based pricing could be particularly important for uptake of Kymriah as it expands its licensed indications; its effects may be much less compelling in other diseases, necessitating a lower price for these patients.

Commenting on its plans for extending its outcomes-based pricing to its new first-in-class treatment, Joe Jimenez said:

"Novartis has been at the forefront of outcomes-based pricing and is very pleased to work with CMS on this first-of-its-kind collaboration with a technology that has the potential to transform cancer care. We look forward to continuing to work with CMS to potentially expand this approach to other products and disease states."

profile mask

Andrew McConaghie

30 August, 2017